EUROLAB
ph-eur-2246-chromatographic-separation-for-impurity-analysis
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH E14: QT Interval Evaluation and Impurity ImpactICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationICH S9: Impurities in Oncology ProductsISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.20: Limit Test for Heavy Metals in ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1031>: The Biocompatibility of Materials and ImpuritiesUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1088>: Forced Degradation Studies for Impurity CharacterizationUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1099>: Acceptable Analytical Performance CriteriaUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1222>: Terminal Sterilization Impact on ImpuritiesUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1231>: Water for Pharmaceutical Purposes and Impurity EffectsUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <905>: Uniformity of Dosage Units Affected by ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

Comprehensive Guide to Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis Laboratory Testing Service Provided by Eurolab

Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis is a laboratory testing service that involves the separation and quantification of impurities in pharmaceutical substances using chromatographic techniques. This standard is governed by the European Pharmacopoeia Commission, which is responsible for developing and publishing standards for medicinal products.

The legal and regulatory framework surrounding this testing service is based on various international and national standards, including:

  • International Organization for Standardization (ISO) 17025:2017 - General requirements for the competence of testing and calibration laboratories
  • European Pharmacopoeia Commissions Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis
  • International Conference on Harmonisation (ICH) Q3A(R2): Impurities: Guiding Principles R2
  • US FDA Guidance for Industry: Impurities in New Drug Submissions
  • These standards ensure that laboratory testing services, such as the one provided by Eurolab, adhere to strict quality and safety requirements.

    The international and national standards that apply to this specific laboratory test are:

  • Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis
  • ISO 17025:2017 - General requirements for the competence of testing and calibration laboratories
  • ICH Q3A(R2): Impurities: Guiding Principles R2
  • Standard development organizations, such as the European Pharmacopoeia Commission and the International Organization for Standardization (ISO), play a crucial role in developing and updating standards. These organizations ensure that standards are periodically reviewed and updated to reflect changes in technology, scientific knowledge, and regulatory requirements.

    The consequences of not performing this test can be severe, including:

  • Non-compliance with regulatory requirements
  • Product recalls or withdrawals from the market
  • Financial losses due to product failures or contamination
  • Damage to brand reputation and customer trust
  • Industries that require Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis testing include:

  • Pharmaceutical industry
  • Biotechnology industry
  • Food industry
  • Cosmetics industry
  • Risk factors associated with this testing service include:

  • Non-compliance with regulatory requirements
  • Product contamination or failure
  • Financial losses due to product recalls or withdrawals from the market
  • Damage to brand reputation and customer trust
  • Quality assurance and quality control measures are essential in ensuring the accuracy and reliability of test results. These measures include:

  • Calibration and validation of equipment and instruments
  • Training and certification of personnel
  • Use of certified reference materials and standards
  • Regular maintenance and calibration of equipment
  • This testing service contributes to product safety and reliability by detecting impurities that may affect product efficacy or pose a risk to human health.

    Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis is a critical laboratory test required to ensure the quality and safety of pharmaceutical substances. This testing service is necessary due to:

  • Regulatory requirements
  • Product safety and reliability
  • Quality assurance and compliance benefits
  • Competitive advantages and market positioning
  • Consequences of not performing this test include:

  • Non-compliance with regulatory requirements
  • Product recalls or withdrawals from the market
  • Financial losses due to product failures or contamination
  • Damage to brand reputation and customer trust
  • Business and technical reasons for conducting Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis testing include:

  • Ensuring compliance with regulatory requirements
  • Detecting impurities that may affect product efficacy or pose a risk to human health
  • Maintaining quality assurance and control measures
  • Enhancing competitive advantages and market positioning
  • Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis testing involves the separation and quantification of impurities in pharmaceutical substances using chromatographic techniques.

    Step-by-step explanation of how the test is conducted:

    1. Sample preparation

    Weighing and mixing of sample with solvent

    Filtration or centrifugation to remove particulate matter

    2. Testing equipment and instruments

    High-performance liquid chromatography (HPLC) system

    Mass spectrometry (MS) detector

    3. Testing environment requirements

    Temperature: 20C 5C

    Humidity: 40-60

    Pressure: atmospheric pressure

    4. Sample preparation procedures

    Weighing and mixing of sample with solvent

    Filtration or centrifugation to remove particulate matter

    5. Testing procedures

    Injection of sample into HPLC system

    Separation of impurities using chromatographic techniques

    Detection and quantification of impurities using MS detector

    This testing service is performed in accordance with Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis and ISO 17025:2017 - General requirements for the competence of testing and calibration laboratories.

    Quality Control Measures

    Eurolab maintains strict quality control measures to ensure the accuracy and reliability of test results, including:

  • Calibration and validation of equipment and instruments
  • Training and certification of personnel
  • Use of certified reference materials and standards
  • Regular maintenance and calibration of equipment
  • These measures are essential in ensuring compliance with regulatory requirements and maintaining product safety and reliability.

    Conclusion

    Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis is a critical laboratory test required to ensure the quality and safety of pharmaceutical substances. This testing service is necessary due to regulatory requirements, product safety and reliability, quality assurance and compliance benefits, and competitive advantages and market positioning.

    Eurolabs experienced team of analysts and state-of-the-art equipment ensure accurate and reliable test results. We maintain strict quality control measures to ensure compliance with regulatory requirements and maintain product safety and reliability.

    For more information on Ph. Eur. 2.2.46: Chromatographic Separation for Impurity Analysis testing services, please contact us at insert contact information.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    Latest News

    View all

    JOIN US
    Want to make a difference?

    Careers